Categories
Loading...
Categories
Shukra Pharmaceuticals has announced its financial results for the fourth quarter and fiscal year ended March 31, 2026. For the quarter, standalone total income from operations reached 7.25 Cr, yielding a net profit of 1.73 Cr. On a consolidated basis, total income stood at 7.27 Cr, with a net profit of 0.72 Cr. Basic and diluted Earnings Per Share for the quarter were 0.04. The company's equity share capital is 43.79 Cr. These figures provide a snapshot of the company's recent financial performance.